* Core Laboratories NV CLB.N CLB is expected to show a fall
in quarterly revenue when it reports results on April 21.
* The Amsterdam, Noord-holland-based company is expected to
report a 27.4% decrease in revenue to $110.696 million from
$152.4 million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Core Laboratories NV is
for earnings of 13 cents per share. For the same quarter last
year, the company reported earnings of 31 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 4 "strong buy" or "buy," 8
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Core
Laboratories NV is $31.5, about 13.1% above its last closing
price of $27.36.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Dec. 31 2020 0.15 0.15 0.18 Beat 16.5
Sep. 30 2020 0.13 0.15 0.16 Beat 9.2
Jun. 30 2020 0.10 0.10 0.14 Beat 42.1
Mar. 31 2020 0.31 0.34 0.31 Missed -7.5
Dec. 0.37 0.37 0.38 Beat 2.2
31 2019
Sep. 30 2019 0.49 0.49 0.50 Beat 2.8
Jun. 30 2019 0.46 0.46 0.46 Met 0.5
Mar. 31 2019 0.43 0.43 0.44 Beat 2.5
This summary was machine generated April 19 at 21:25 GMT